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Abstract
Background: Recent studies show that inflammatory processes may contribute to neuropathic pain. Cyclooxygenase-2 (Cox-
2) is an inducible enzyme responsible for production of prostanoids, which may sensitise sensory neurones via the EP1 receptor.
We have recently reported that while macrophages infiltrate injured nerves within days of injury, they express increased Cox-
2-immunoreactivity (Cox-2-IR) from 2 to 3 weeks after injury. We have now investigated the time course of EP1 and Cox-2
changes in injured human nerves and dorsal root ganglia (DRG), and the chronic constriction nerve injury (CCI) model in the rat.
Methods: Tissue sections were immunostained with specific antibodies to EP1, Cox-2, CD68 (human macrophage marker) or
OX42 (rat microglial marker), and neurofilaments (NF), prior to image analysis, from the following: human brachial plexus nerves
(21 to 196 days post-injury), painful neuromas (9 days to 12 years post-injury), avulsion injured DRG, control nerves and DRG,
and rat CCI model tissues. EP1 and NF-immunoreactive nerve fibres were quantified by image analysis.
Results: EP1:NF ratio was significantly increased in human brachial plexus nerve fibres, both proximal and distal to injury, in
comparison with uninjured nerves. Sensory neurones in injured human DRG showed a significant acute increase of EP1-IR
intensity. While there was a rapid increase in EP1-fibres and CD-68 positive macrophages, Cox-2 increase was apparent later,
but was persistent in human painful neuromas for years. A similar time-course of changes was found in the rat CCI model with
the above markers, both in the injured nerves and ipsilateral dorsal spinal cord.
Conclusion: Different stages of infiltration and activation of macrophages may be observed in the peripheral and central
nervous system following peripheral nerve injury. EP1 receptor level increase in sensory neurones, and macrophage infiltration,
appears to precede increased Cox-2 expression by macrophages. However, other methods for detecting Cox-2 levels and
activity are required. EP1 antagonists may show therapeutic effects in acute and chronic neuropathic pain, in addition to
inflammatory pain.
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Background
Tissue damage induces an inflammatory response includ-
ing the production of prostaglandins (PGs) such as PGE2,
which activate the EP1 receptor expressed by sensory
fibres. PGs produced in the spinal cord may also play an
important role in the development of hypersensitivity fol-
lowing peripheral nerve injury [1]; PGs generated by Cox-
2 in the spinal cord have been shown to contribute to the
maintenance of hyperalgesia [2].
The enzymes involved in the production of PGs are
cyclooxygenases (Cox) of which Cox-1 was at first thought
to be the only enzyme present. Subsequently, it was found
that Cox activity could be induced by inflammatory
cytokines, suggesting the existence of a second isoform.
This was confirmed by the isolation of a second cyclooxy-
genase gene encoding Cox-2 [3]. The classical view that
Cox-1 was constitutive and that Cox-2 was exclusively a
pro-inflammatory inducible enzyme [4] was challenged
since both isoforms are present in different tissues and
sites of inflammation, and induced differentially [5,6].
Cox-2 protein is upregulated in a number of non-neuro-
nal cell types such as macrophages, human monocytes,
synoviocytes, and microglia in CNS inflammation [7,8].
Data indicate that Cox-2 is strongly involved in different
processes of central nervous modelling and regulated by
different signalling pathways. The explicit roles of the con-
stitutive enzyme in the pain and inflammatory processes
remains to be fully determined [9]. Evidence that prosta-
noids could sensitise the peripheral nerve terminals [10]
has triggered new research in the Cox enzymes involved in
the biosynthesis of PGs to develop inhibitors (Coxibs) of
potential therapeutic value.
The contribution of prostanoids such as PGE2 or PGE2α in
inflammatory processes [11] and in pain modulation has
well been defined [12,13] and reviewed [14]. PGE2 signals
via a transmembrane G-protein coupled receptor (EP), of
which four types have been identified (EP1-4) [13,15].
EP1 receptor stimulation mediates increases in intracellu-
lar calcium ions (Ca2+), facilitating neurotransmitter
release [16,17]. EP1 receptor involvement in pain mecha-
nisms has been described in animal studies [18,19]. EP
receptor antagonists have provided evidence of a role for
EP receptors in reducing hyperalgesia and allodynia in
rodents [20]. Localisation studies have revealed that EP1
mRNA is expressed in rat DRG neurones [21-23]. A recent
study demonstrated that PGE2, via the EP1 receptor, con-
tributed to human visceral pain hypersensitivity [24]. The
emerging general consensus of animal and human studies
identifies the EP1 receptor as a selective target of therapeu-
tic value, of similar analgesic effect as non-steroidal anti-
inflammatory drugs (NSAIDs), but with fewer potential
side effects [18].
Activation of immune-like glial cells such as astrocytes or
microglia has been reported in numerous conditions, and
may contribute to hyperalgesia, mechanical allodynia or
chronic inflammatory pain in animal models. Microglia
are phagocytic, cytotoxic and antigen-presenting cells that
upon activation are involved in a pattern of cellular
responses, including proliferation, recruitment to the site
of injury and increased expression of immunomolecules
[25]. Glial activation can be induced by substances
released from neurones such as PGs, nitric oxide, fractalk-
ine, substance P, excitatory amino acids and adenosine 5'-
triphosphate (ATP) [26], and in turn, result in the release
of numerous inflammatory agents such as cytokines,
growth factors, kinins, purines, amines, prostanoids and
ions [27]. These inflammatory agents have been shown to
activate and/or enhance the sensitivity of primary affer-
ents and spinal cord neurones, and thus glial activation
may play a role in nociceptive processing [28-31]. How-
ever, some studies report lack of correlation of neuro-
pathic pain behaviour with levels of microglial activation
in animal models [32].
The aim of this study was to investigate the time-course of
key neuronal-inflammatory interactions in injured
human nerves and DRG, and in the CCI rat model. Mac-
rophage/microglia-like cells, Cox-2 and EP1 receptor lev-
els were studied, using immunocytochemistry and
Western blotting.
Methods
Human tissue
Fully informed consent was obtained for all tissues, which
were collected with approval of the Local Ethics Commit-
tee. Injured human nerve specimens (proximal and distal
to site of injury) were obtained during surgery for brachial
plexus repair [n = 11; acute (< 21 days), n = 5, 5 males, age
range 20–66 years; chronic (> 21 days) n = 6, 4 males and
2 females, age range 24–35 years] and avulsed DRG [n =
11; acute (< 21 days) n = 5, 5 males, age range 18–39
years; chronic (> 21 days), n = 6, 5 males and 1 female, age
range 21–39 years]. Painful human distal limb neuromas
were obtained during surgery (n = 12; 9 males and 3
females; age range 26–63 years; injury duration from 9
days to 12 years) – the mean pain scores on a visual ana-
logue scale (VAS) were all > 4 out of 10 at the time of sur-
gery, and patients reported this or a higher level of pain
usually continuously since the time of injury. Uninjured
control human nerve tissue (n = 9, 5 males and 4 females,
age range 39–77 years) was obtained during surgery for
limb amputation for non-neurological tumours from
patients with no neurological symptoms or signs. Con-
trol, post-mortem DRG (n = 7, 2 males and 5 females, age
range 34–88) were obtained from Netherlands Brain Bank
with a post-mortem delay of less than 12 h. Tissues wereBMC Neurology 2006, 6:1 http://www.biomedcentral.com/1471-2377/6/1
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snap frozen in liquid nitrogen and stored at -70°C until
use.
Rat tissue
Adult male Sprague-Dawley rats (n = 32; 200–250 g) were
used in this study. CCI animals (n = 16) had the left sciatic
nerve loosely ligated with chromic gut sutures to cause a
constriction injury. Control, sham-operated animals (n =
16) underwent identical surgical procedures but without
nerve constriction. In brief, under isoflurane anaesthesia,
the common left sciatic nerve was exposed at mid thigh
level. Four loose ligatures of chromic gut (4.0) were tied
loosely around the nerve with a spacing of 1 mm between
each. The wound was then closed and secured with suture
clips. The surgical procedure was identical for the sham-
operated animals except the sciatic nerve was not ligated.
CCI-induced decrease in mechanical paw withdrawal
threshold was measured using an algesymeter [33]. To
determine threshold, an increasing weight was applied to
the dorsal surface of the left and right hindpaw until the
rat attempted to withdraw the paw. To study glial activa-
tion and Cox-2 expression, animals were sacrificed on
days 4, 21, and 30 (n = 4 in each experimental group and
for each time point) and tissues harvested. Left and right
sciatic nerve (nerve tissue from 4 days post-operation only
was available for this study), and lumbar spinal cord were
collected. Tissues were snap frozen in 2-methyl butane
cooled in liquid nitrogen and stored at -70°C until use.
All procedures involving the use of animals were
approved by the UK Home Office and were carried out in
accordance with the requirements of the project licence.
Immunocytochemistry
Tissues were supported in optimum cutting tissue (OCT)
medium (Raymond A Lamb Ltd, Eastbourne, UK) to
allow best orientation (transverse for spinal cord, longitu-
dinal for nerve). Frozen sections (10 µm thick) were col-
lected onto poly-L-lysine (Sigma, Poole, UK) coated glass
slides and post-fixed in freshly prepared 4% w/v parafor-
maldehyde in 0.15 M phosphate buffered saline (PBS) for
30 min. Endogenous peroxidase was blocked by incuba-
tion in industrial methylated spirit (IMS) containing 0.3%
w/v hydrogen peroxide. After rehydration, sections were
incubated overnight with primary antibody. The primary
antibodies for EP1 were polyclonal rabbit anti-human
EP1 receptor antibody (1:500, Cayman Chemical, Bing-
ham, UK) and polyclonal rabbit anti mouse EP1 receptor
antibody (1:500, Alpha Diagnostic International, San
Antonio, Texas, USA), which showed similar results
(results shown for Cayman antibody only). Other primary
antibodies used included monoclonal anti-Cox-2 anti-
body (1:250, Transduction Laboratories, Cowley, UK,
Clone33), monoclonal mouse anti-CD68 as a well-estab-
lished marker of human macrophages [34], described in
numerous previous publications (1:500, Dako, Ely, UK,
Clone EBM11), mouse anti-rat CD11b antibody as a mac-
rophage/microglial marker in rats (1:1000, Serotec, Kid-
lington, UK, CloneMRC OX42), a monoclonal mouse
antibody to the neurofilament phosphorylated and non-
phosphorylated 200 kDa molecular forms (1:50000,
Sigma Laboratories, Saint-Louis, MI, USA, Clone N52)
and a rabbit polyclonal antiserum antibody cocktail to
neurofilaments (1:5000, Affinity Research Products Lim-
ited, Exeter, UK). The rat microglial marker (OX42/
CD11b) previously showed similar levels of expression in
CCI rat tissue as with another microglial marker ([3H] (R)
PK11195) [35]. Sites of primary antibody attachment
were revealed using nickel-enhanced, avidin-biotin perox-
idase (ABC – Vector Laboratories, Peterborough, UK) as
formerly described [36]. Sections were counter-stained for
nuclei in 0.1% w/v aqueous neutral red, dehydrated and
mounted in xylene-based mountant (DPX; BDH/Merck,
Poole, UK), prior to photomicrography. Negative controls
without primary antibody were incubated with normal
rabbit or mouse serum. EP1 peptide antigen from Glaxo-
SmithKline/Cayman Chemicals was used at 10-1 to 10-6
mg/ml and pre-incubated with anti-EP1 (Cayman) at 1/
5000 on a control DRG and at 1/2000 on an acute injured
DRG. Both control and injured DRG showed reduced
staining at high (10-1 – 10-2 mg/ml) concentrations of
peptide antigen, compared to sections stained in the pres-
ence of antibody alone.
Immunoreactive cells were quantified by computerized
image analysis (Seescan Cambridge, UK). Analogue
images were captured via video link to an Olympus BX50
microscope and converted into a digital monochrome
image by the computer. The grey-shade detection thresh-
old was set at a constant level to allow detection of posi-
tive immunostaining and the area of highlighted
immunoreactivity was expressed as a % area of the field
scanned. One section per nerve specimen was image-ana-
lysed at the stated optimum dilution (this followed a
series of 5 sections immunostained with 5 different anti-
body dilutions). The visual fields were selected at random,
avoiding edges of the section. The area was 442 µm ×
332.8  µm. Three to five fields per tissue section were
scanned and the mean value was used in subsequent sta-
tistical analysis. For DRG, the intensity of immunoreac-
tion of sensory neurones was assessed in blinded fashion
by two observers at two dilutions of antibodies and given
a mean score (vision inspection scale: 0 = no immunore-
action; 1 = weak; 2 = medium; 3 = strong). DRG neurones
were counted in the entire section (mean 54.58; range 34–
87) per DRG.
Western blotting
Brachial plexus nerves from 4 controls and 8 injured
patients (3 acute and 5 chronic injured) were available for
Western blotting. Note that only 3 samples for the acuteBMC Neurology 2006, 6:1 http://www.biomedcentral.com/1471-2377/6/1
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group were available (10, 15 and 17 days of injury dura-
tion) and represent the latter stage of the "acute" phase.
Nerve extracts and mouse macrophage control extracts
(Transduction Labs, Cowley, UK) were processed for
Western blotting as described [37]. Briefly, non-specific
antibody binding sites were blocked by incubating the
strips in 5% (w/v) non-fat dried milk in a solution of PBS
containing 0.1% (v/v) Tween 20 for 1 h. Primary antibody
incubation was 2 h or overnight in block buffer (Cox-2 at
a titre of 1:2000). After washing, sites of attachment of pri-
mary antibodies were detected using immunoperoxidase
reagents (Vector Laboratories, Peterborough, UK). Immu-
noreactivity using chemiluminescence was visualised on
Hyperfilm film after treatment with Electrophoresis
Chemiluminescence (ECL)-plus Western blotting detec-
tion system (Amersham Biosciences Ltd, Little Chalfont,
UK). Optical density readings of each Hyperfilm were
taken using a Digit-X densitometer (X-Ograph Ltd, Tet-
bury, UK) evenly illuminated on a photography viewer.
Background readings were determined by measuring opti-
cal density outside the sample lanes. After subtraction of
background, the mean of three consecutive readings of
protein immunoreactivity at the 70-kDa positions for
each sample lane was obtained.
Statistical analysis
Descriptive statistics were generated using Microsoft Excel
2000 for Windows (Microsoft, Redmond, WA, USA) and
GraphPad Prism version 3.00 for Windows (GraphPad
Software, San Diego California, USA). Group differences
were assessed using a nonparametric test, the Mann-Whit-
ney U test (one-tailed), in GraphPad Prism. Statistical sig-
nificance was considered at P < 0.05.
Results
Human brachial plexus nerves and DRG
Both EP1 antibodies showed immunoreactivity in nerve
fibres (Figure 1A), which appeared more intense in acute
injured nerves (Figure 1B). The results of image analysis
are given below. In human DRG, EP1 immunoreactivity
(EP1-IR) was detected in small/medium diameter neu-
rones of control (Figure 1C) and injured human DRG
(Figure 1D). A significant increase of intensity was
observed using the visual inspection scale in DRG sensory
neurones after injury in the acute group (surgery delay <
21 days; 3.5 ± 0.34) compared to control DRG (2.57 ±
0.20, p = 0.02). Chronic injured DRG were not signifi-
cantly different (2.83 ± 0.17).
EP1 and NF-immunoreactive nerve fibres were quantified
by image analysis (% immunopositive area) in injured
and control nerves and expressed as the ratio EP1:NF (Fig-
ure 2). EP1-IR:NF-IR ratio was significantly higher in
injured acute proximal (0.17 ± 0.05; n = 5; p < 0.03) and
distal (0.22 ± 0.69; n = 5; p < 0.01) and injured chronic
proximal (0.19 ± 0.06; n = 6; p < 0.01) and distal (0.33 ±
EP1-IR:NF-IR ratio in human proximal and distal injured  nerves Figure 2
EP1-IR:NF-IR ratio in human proximal and distal 
injured nerves. Significant increases of EP1-IR:NF-IR ratios 
were observed in human nerves proximal and distal to injury 
when compared to uninjured nerves. * p < 0.03; ** p < 0.01.
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EP1 immunoreactivity in human injured brachial plexus  nerves and avulsed DRG Figure 1
EP1 immunoreactivity in human injured brachial 
plexus nerves and avulsed DRG. EP1-IR was observed in 
nerve fibres in control nerves (A) and appeared more intense 
in injured nerves (B). EP1-IR was detected mainly in some 
small/medium diameter neurones (arrowheads) of control 
(C) and more so in injured human DRG (D). Scale bars = 50 
µm.
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0.18; n = 6; p < 0.01) nerves compared to controls (0.03 ±
0.01; n = 5).
A time course analysis of EP1-IR:NF-IR ratio and Cox-2-IR
in human brachial plexus nerves showed that EP1 expres-
sion preceded Cox-2-IR increased levels (Figure 3). Simi-
lar results were found with both EP1 markers.
A 70 kDa Cox-2 band was observed in mouse macrophage
control and human nerve extracts, which was clearly more
prominent in the acute nerves (Figure 4). The optical den-
sity of the Cox-2 70kDa band was significantly increased
(p = 0.02) in the acute group (1.41 ± 0.04, n = 3) com-
pared to control nerves (0.55 ± 0.09, n = 4). No statistical
significant difference was detected for the chronic group
(0.61 ± 0.09, n = 5).
Human painful neuromas
Few, scattered microglial/macrophage-like, Cox-2 immu-
noreactive cells were found throughout the uninjured
human nerve tissue (Figure 5A). Similar cells, but with
more abundance were observed in the painful neuromas
(Figure 5B). Immunostaining for CD68 showed cells with
similar morphology and distribution to Cox-2 in controls
(Figure 5C), with an increase in neuromas (Figure 5D.).
Image analysis showed Cox-2-IR (in % area) to be signifi-
cantly greater in human neuromas (0.79 ± 0.14; n = 12; p
= 0.0022) than in controls (0.32 ± 0.04; n = 13; Figure 6).
A similar increase was found with the macrophage marker
CD68. CD68 immunoreactivity (CD68-IR) was signifi-
cantly increased in human limb neuromas (8.96 ± 0.99; n
= 12; p < 0.0001) compared to the control group (0.32 ±
0.04; n = 13).
A time course analysis of injury duration (time elapsed
between the injury and the removal of the neuroma) dem-
onstrated an immediate increase in CD68-IR, which
remained above control levels during the entirety of the
time course (Figure 7). Cox-2-IR increases, as previously
described, were only apparent from 2 to 3 weeks after
injury [35], and persistent for years.
Few nerve fibres showed some EP1 immunoreactivity but
fibres were too sparse to show significant statistical differ-
ence.
CCI rat model studies
Unilateral constriction injury to the sciatic nerve resulted
in a reduction in paw withdrawal threshold ipsilateral to
the nerve injury, usually evident at 9 days and maintained
until after 30 days post-operation (in these rats, at 30 days
post-operation: CCI, 88.12 ± 7.04 g; n = 8, sham 127.5 ±
75.13 g; n = 8). Following behavioural testing on day 04,
21 and 30, the animals were humanely sacrificed and tis-
sues prepared for immunocytochemistry. Sham operation
had no significant effect on paw withdrawal threshold
compared to basal levels.
In rat nerve, Cox-2-IR and CD68-IR were found in cells
similar to those seen in human nerve tissue as previously
described [35]. Few scattered Cox-2 positive cells were
seen within the nerve fascicles in sham-operated or con-
trol nerves. In CCI nerve, these cells appeared more
numerous proximal to the injury site, but this was not sta-
tistically significant at 4 days and showed only a trend (p
= 0.057); in our previous study, we have shown a signifi-
cant increase at 40 days post-surgery [35]. Antibodies to
the rat macrophage/activated microglia marker (CD11b-
OX42) showed few positively stained cells in sham-oper-
ated or control nerves (Figure 8), and an abundance of
positively stained cells in day 4 post CCI-lesioned nerves
(n = 4, 4.58 ± 0.46) compared to sham-operated nerves (n
= 4, 0.26 ± 0.02; p < 0.001, Figure 9).
In the spinal cord of sham-operated rats at all time points,
small, microglial-like Cox-2-immunoreactive cells, with
some fine processes, were scattered throughout the grey
matter and the white matter (Figure 10A). These cells
tended to be less prevalent in the grey matter of CCI rat
spinal cords at earlier time points (4, 21 and 30 days; Fig-
ure 10B). The macrophage/activated microglia marker
(CD11b-OX42) showed small, scattered cells of similar
morphology to Cox-2 immunoreactive cells, usually with
several processes (Figure 10C). These cells appeared to
increase in number and intensity in the spinal cord on the
side of the nerve lesion, mainly in the superficial dorsal
horn (Laminae I-II) and the ventral horn (Laminae IX, Fig-
ure 10D).
EP1-IR:NF-IR ratio and Cox-2-IR in proximal brachial plexus  injured nerves – time course Figure 3
EP1-IR:NF-IR ratio and Cox-2-IR in proximal brachial 
plexus injured nerves – time course. The time course of 
EP1-IR:NF-IR ratio and Cox-2-IR showed that EP1 preceded 
Cox-2-IR increased levels.
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Quantification of Cox-2-IR in the time course showed sig-
nificantly (p < 0.02) lower levels in the lesioned superfi-
cial dorsal horn of the spinal cord compared to sham-
operated at all three time points (Figure 11). Quantifica-
tion of OX42-IR showed increased significant levels of
OX42-IR across the time course (p < 0.03) and across the
main three areas in the lesioned side of the spinal cord –
superficial dorsal horn (Figure 11), deep dorsal horn
(data not shown) and ventral horn (data not shown).
Discussion
Tissue damage generates an inflammatory response result-
ing in release of inflammatory mediators that in turn
causes pain and hyperalgesia. Macrophages, other immu-
nocompetent cells, as well as increased levels of cytokines
have been found in injured nerves and DRG [35,38,39].
Macrophages have been found to be the predominant
source of prostanoid release [40,41]. Prostanoids sensitise
peripheral nerve terminals, and are also produced and
released in the spinal cord following peripheral nerve
injury, establishing both peripheral and CNS links
between prostaglandin production and hypersensitivity
[10,42].
In the present study, the time course of macrophage/
microglia-like cell activation was studied in comparison
with Cox-2 levels and EP1 receptor levels in human
injured nerves and a rodent model of nerve injury. EP1
receptor levels were reported for the first time in human
nerve fibres and DRG, and appeared increased in acutely
injured tissues. The greater increase distally of EP1 was a
trend, and not statistically significant, and could be the
result of increased EP1 in regenerating or spared fibres.
The EP1 time course when compared to the previously
published time course of Cox-2 [35] showed rapid ele-
vated levels of EP1 receptor in proximal nerves. The previ-
ous paper reported both proximal and distal nerve
staining, but only proximal nerve stumps were used to
compare directly with EP1 immunostaining for the same
specimens in this study. In accord with our previous
report [35], Cox-2-IR was increased from some weeks after
injury, whereas CD68-positive macrophages were
increased more acutely – in this study, we have demon-
strated, in addition, that the Cox-2-IR increase in macro-
phages persists over many years in injured human
Cox-2 and CD68 immunoreactive cells in uninjured nerves  and human neuromas Figure 5
Cox-2 and CD68 immunoreactive cells in uninjured 
nerves and human neuromas. Very few scattered Cox-2 
immunoreactive cells were found in uninjured human nerve 
tissue (A) compared to human neuromas (B). CD68 immu-
noreative cells were of similar morphology and distribution 
as Cox-2 and were observed with greater abundance in 
injured nerve (D) than in control (C). Magnification bars = 50 
µm.
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Cox-2 70-kDa band by Western blots Figure 4
Cox-2 70-kDa band by Western blots. Cox-2 70-kDa band in control nerve (A), acute injured nerve (B) and chronic 
injured nerve (C). The Cox-2 70 kDa band was clearly more prominent in the acute nerves.
A - Control B - Acute C - ChronicBMC Neurology 2006, 6:1 http://www.biomedcentral.com/1471-2377/6/1
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neuromas. After injury nerves show rapid swelling and
oedema formation. Due to this swelling, the % positive
areas measured might account for the lower levels of Cox-
2-IR with image analysis compared to controls – when we
analysed our nerves by counting positive cell numbers per
area, no significant change (i.e. no decrease) was
observed. A 70 kDa Cox-2 band was significantly
increased in acute injured human nerve extracts, but not
chronic, and are apparently discrepant with immunohis-
tochemical findings – this may reflect the time-points at
which limited numbers of nerves were available in suffi-
cient quantities to enable western blotting studies, as only
those clustering around the broad peak of Cox-2 increase
(2 – 8 weeks) would be expected, and showed, significant
increase. The nerve samples extracts that constitute the
Western blotting "acute" group represented the later stage
of the acute phase i.e., 10, 15 and 17 days, and the
"chronic" group included 3 out of 5 samples beyond 10
weeks after injury.
In the CCI rat model, numerous OX42-IR macrophage/
microglial-like cells appeared in the injured sciatic nerves,
as well as in the superficial dorsal horn of the spinal cord
in CCI rats, at 4 days post operation. However, while there
was a trend, Cox-2-IR was not significantly increased in
nerves. A similar change was also found at 21 days post-
operation in CCI nerve tissue in recent different set of ani-
mals (data not included); a significant increase of Cox-2-
IR at 40 days post-injury in CCI nerve was reported by us
previously [35]. In this study Cox-2 immunoreactivity just
failed to reach significance at days 4 and 21 in the CCI
rats, possibly because the increase was not as robust as at
day 40 after injury, and/or due to a smaller number of ani-
mals in the present study. Two cited papers [43,44]
showed an upregulation of Cox-2 in CCI and partial nerve
ligation nerves at 2 and 4 weeks after injury, also in mac-
rophages, but they counted Cox-2 positive cells per area in
one study and a comparison between sham and CCI con-
tralateral sciatic nerve was not assessed [43], whereas we
image-analysed % area of the sections and conducted sta-
tistical comparison, which may account for the differences
in our studies. When we re-analysed our CCI nerves by
counting positive cell numbers per area, a trend for an
increase was observed but this still did not achieve statis-
tical significance (data not shown). In another study,
when Cox-2 positive cells were compared between ipsi-
and contralateral sciatic nerve (modified Chung model),
not all time points (i.e. 3 days) reached levels of signifi-
cance [45].
In the CCI rat spinal cord, a significant increase of OX42
immunoreactive macrophage/microglial-like cells was
observed over the entire time course (4–30 days) in the
lesioned side superficial dorsal horn; however, Cox-2-IR
was, surprisingly, found to be decreased at all these time
points. Sufficient tissues were not available for Western
blotting of Cox-2 in rat spinal cord, but are necessary to
substantiate present findings. The underlying mecha-
nisms and significance of this decrease remain hence
uncertain; it should be noted that we have previously
reported using the same methods that Cox-2 immunore-
active macrophage-like cells in the nerves and in the
lesioned superficial dorsal horn of the CCI rats were
increased above normal levels at 40 days post operation,
Cox-2-IR and CD68-IR in human neuromas – time course Figure 7
Cox-2-IR and CD68-IR in human neuromas – time 
course. Rapid increase of CD68 immunoreactive cells was 
observed, whilst Cox-2-IR was only apparent from 2 to 3 
weeks as previously described and remained persistent over 
many years.
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Cox-2-IR and CD68-IR in human painful neuromas Figure 6
Cox-2-IR and CD68-IR in human painful neuromas. 
Cox-2-IR and CD68-IR (in % area) are significantly increased 
in injured nerves compared to control nerves. * p < 0.002; ** 
p < 0.0001.
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suggesting a delay in the expression of Cox-2 [35]. Struc-
tural reorganisation in the spinal cord after peripheral
nerve injury [46] could account for the delayed expression
of Cox-2 in macrophage/microglial-like cells.
A number of other studies have described Cox-2 changes
in different cell types in animal models of nerve injury.
Using a modified Chung model, where only L5 was sev-
ered [47,48], different stages of Cox-2 expression were
observed in the sciatic nerve, with an early or first phase
(after 1 day), where Cox-2-IR was co-localised with a
Schwann cell marker, followed by a second phase, involv-
ing macrophages [45]. In the spared nerve injury (SNI)
model [49], a small increase in Cox-2 mRNA protein was
demonstrated in the dorsal horn at 24 hours post surgery,
returned to sham levels at 72 hours, and was decreased at
7 days [50]. Furthermore, Cox-2-IR was shown by immu-
nohistochemical methods to be only slightly increased in
the deeper layers of the L4–L5 dorsal horn of the spinal
cord at 10 hours post surgery. In this study pain behaviour
in the rats was apparent from 9 days and maintained until
30 days post operation, which suggests that the neuro-
pathic pain behaviour tested was not correlated, at the
time-points studied, with significantly increased Cox-2
expression, in accord with the findings of some other
investigators [32].
In a rodent partial nerve ligation study, EP1-IR was found
near the sciatic nerve ligation site, in nuclei of cells co-
expressing the macrophage marker ED1 [51]. However, in
the present study, we found EP1 receptors to be mainly
expressed in axons and cell bodies of human sensory neu-
rones. The regulation of EP1 receptors in injured sensory
neurones and inflammatory cells deserves further investi-
gation. The molecular regulators of EP1 expression in
DRG neurons are unknown – trauma and initial inflam-
matory response (shown by rapid increases of CD68-IR)
may lead to increased EP1 levels, to which PGs may con-
tribute. Later, Cox-2 expression in macrophages may be
involved in the persistence of pain. The time-course of
Cox-2 expression also suggests a role in the processes of
Wallerian degeneration and regeneration. Further investi-
gations are required, including studies of chronic non-
painful human neuromas, to establish a link between EP1
and Cox-2 levels with pain.
A number of clinical and animal model pharmacological
studies suggest that Cox-2 and EP1 are key therapeutic tar-
gets in inflammatory and neuropathic pain. The selective
Cox-2 inhibitor, GW406381X, was shown to be effective
in reducing mechanical allodynia in the CCI rat model,
and thermal hyperalgesia in the mouse partial ligation
model, both animal models of neuropathic pain [47].
GW406381X was also effective in reducing pain behav-
iour when given intrathecally and orally to rats with cap-
Cox-2-IR and OX42-IR in sham-operated and CCI lesioned  rat nerve at 4 days post-operation Figure 9
Cox-2-IR and OX42-IR in sham-operated and CCI 
lesioned rat nerve at 4 days post-operation. At 4 days 
post-operation, OX42-IR was significantly increased in 
lesioned nerves compared to sham-operated nerves whilst 
Cox-2-IR was not significantly increased. * p < 0.015.
0.0
0.1
0.2
0.3
0.4
0.5
0.6 Sham-operated
CCI
0
1
2
3
4
5
6
Cox-2 OX42
*
C
o
x
-
2
-
I
R
(
%
a
r
e
a
)
O
X
4
2
-
I
R
(
%
a
r
e
a
)
Cox-2 and OX42 immunoreactive cells in sham and CCI rat  nerve at 4 days post operation Figure 8
Cox-2 and OX42 immunoreactive cells in sham and 
CCI rat nerve at 4 days post operation. Very few Cox-
2 immunoreactive cells (arrowheads) were observed in the 
left sciatic nerve of sham-operated (A) compared to CCI (B). 
Similarly, sham-operated nerves (C) showed much less mac-
rophages in the sciatic nerve than CCI nerves (D). Scale bars 
= 50 µm.
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saicin-induced inflammatory pain [52]. The selective Cox-
2 inhibitor, etodolac, administered orally, reduced heat-
evoked hyperalgesia in rats with chronic constrictive sci-
atic nerve injury [53]. Other Cox-2 inhibitors such as
celecoxib and rofecoxib, however, are effective in inflam-
matory pain but do not alter neuropathic pain behaviour.
Intraperitoneal injection of Rofecoxib, a selective cox-2
inhibitor, did not prevent the development of allodynia
and hyperalgesia in the spared nerve injury model [50].
EP1 antagonists may be effective in neuropathic, inflam-
matory and incisional pain models. In the CCI model,
oral administration of an EP1 antagonist from 8 to 14
days post-operation effectively reduced CCI-induced
mechanical hyperalgesia and allodynia [20]. In another
animal model of neuropathic pain (partial ligation of the
sciatic nerve), mechanical and thermal hyperalgesia was
reversed with a EP1 receptor antagonist (SC-19220) [54].
EP1 receptor antagonists reduced the response to forma-
lin-induced inflammation [55,56]. Spinal application of
EP agonists in an inflammatory rat knee joint model dem-
onstrated that EP1, EP2 and EP4 agonists all generated
spinal hyperexcitability similar to PGE2  [57]. In a rat
model of postoperative pain administration of an EP1
antagonist (ONO-8711) generated analgesic effects on
mechanical evoked pain [58,59]. Similar inhibitory effects
on mechanical hyperalgesia with the same EP1 antagonist
were shown in a carrageenan-induced inflammatory
model [60]. The second phase, but not the first phase, of
formalin-induced flinching behaviour in the paw was
effectively inhibited by spinally administered EP1 recep-
tor antagonists (SC-51089 and SC-51234A) [56]. Impor-
tantly, the involvement of PGE2 in sensitisation via the
EP1 receptor has also been shown in human oesophageal
pain hypersensitivity, with the successful use of an EP1
antagonist [24].
Conclusion
In this study, we report that a rapid increase of EP1 recep-
tor levels in injured human sensory neurones preceded
Cox-2 expression in infiltrating macrophages. Chronic
painful human neuromas showed persistence of EP1-IR in
nerve fibres and increased Cox-2-IR macrophages. EP1
antagonists may show therapeutic effects in acute and
chronic neuropathic pain, in addition to inflammatory
pain.
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